### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROV	/AL
OMB Number:	3235-0287
Estimated average bur	den
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person Maynard Ryan D  (Last) (First) (Middle)  RIGEL PHARMACEUTICALS, INC., 1180  VETERANS BLVD.  (Street)				2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director  X_Officer (give title below)  VP Finance, Acting CFO  6. Individual or Joint/Group Filing(Check Applicable Line)  X_Form filed by One Reporting Person  Form filed by More than One Reporting Person				
				3. Date of Earliest Transaction (Month/Day/Year) 08/07/2006					X	w)					
				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ F					
		NCISCO, CA 94									······································		eporting reison		
(Cit	ty)	(State)	(Zip)			Ta	able I - No	on-Deriva	ative Securities	Acquired,	Disposed o	of, or Benef	icially Owned		
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Yea		2A. Deemed Execution Dany		e, if C	Code		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Owned Followin Transaction(s)		( H	Form:	7. Nature of Indirect Beneficial		
			(Mont	h/Day/Y	rear)	Code	V Am	(A) or (D)	(Instr	str. 3 and 4)		(	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
									rm are not re ly valid OMB			nless the t	form display	/S	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	(e.g., p 4. Transact Code	tion of De Sec Ac		Acquired ants, option 6. Date Expirat	current l, Dispose	ed of, or Benef vertible securit ble and	control nu	mber. ed I Amount	8. Price of	9. Number o Derivative Securities Beneficially Owned Following		Beneficia Ownersh : (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	(e.g., p 4. Transact Code	5. 1 tion of De Sec Ac (A) Dis of (	s, warr Number rivative curities quired or sposed (D) str. 3, 4	Acquirectants, option 6. Date Expirat (Month	I, Dispose ons, conv Exercisation Date	ed of, or Benef vertible securit ble and	icially Ownoies)  7. Title and of Underly Securities	mber. d Amount ing d 4)	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned	f 10. Ownersl Form of Derivati Security Direct (I or Indire	nip of Indired Beneficia Ownersh (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	(e.g., p 4. Transact Code	tion of De Sec (A) Dis of (In and	s, warr Number rivative curities quired or sposed (D) str. 3, 4	Acquirectants, opti	I, Dispose ons, conv Exercisal ion Date /Day/Yea	ed of, or Benef vertible securit ble and	icially Ownoies)  7. Title and of Underly Securities	mber. ed I Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	f 10. Ownersl Form of Derivati Security Direct (I or Indirect)	nip of Indired Beneficia Ownersh (Instr. 4)

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Maynard Ryan D RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94306-2155			VP Finance, Acting CFO		

## **Signatures**

/s/ Dolly Vance (Attorney-in-Fact)	08/08/2006
**Signature of Reporting Person	Date

# **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Fifty Per Cent (50%) of the shares vest on the grant date and Fifty Per Cent (50%) of the shares vest monthly thereafter over twenty-four(24) months.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.